ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd (TLSA)

0.85
0.058
( 7.32% )
Updated: 14:17:28

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.050.050.050.050.000.00 %0450-
5.000.000.000.000.000.000.00 %00-

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.000.000.000.000.00 %00-
5.000.000.000.000.000.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STAIScanTech AI Systems Inc
$ 3.7346
(82.18%)
128.74M
EFOIEnergy Focus Inc
$ 2.0607
(59.74%)
43.58M
KWEKWESST Micro Systems Inc
$ 0.7274
(55.76%)
224.26M
ADTXAditxt Inc
$ 0.1025
(46.43%)
640.83M
HCTIHealthcare Triangle Inc
$ 0.6993
(46.02%)
50.68M
INLFINLIF Limited
$ 3.41
(-79.12%)
9.42M
BPTHBio Path Holdings Inc
$ 0.214
(-66.20%)
5.21M
SEPNSepterna Inc
$ 5.5426
(-57.23%)
5.37M
PTPIPetros Pharmaceuticals Inc
$ 0.1331
(-54.57%)
22.82M
RSLSReShape Lifesciences Inc
$ 1.09
(-53.22%)
4.74M
ADTXAditxt Inc
$ 0.1025
(46.43%)
638.82M
KWEKWESST Micro Systems Inc
$ 0.7274
(55.76%)
224.05M
PRPHProPhase Labs Inc
$ 0.4684
(44.12%)
168.12M
INTCIntel Corporation
$ 26.2218
(11.11%)
147.36M
STAIScanTech AI Systems Inc
$ 3.7346
(82.18%)
128.55M

TLSA Discussion

View Posts
Golden Cross Golden Cross 2 hours ago
$TLSA BIG news: More patients dosed with intranasal foralumab in our expanded access program for non-active SPMS. 🚀 Stability or improvement seen in EVERY patient so far. Phase 2 is underway... the future is here.
https://x.com/TizianaLS/status/1891835307680571697
👍️0
MahinAgency MahinAgency 3 hours ago
NASDAQ: $TLSA Big Opportunity⚡️

BREAKING NEWS🎯

''Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program''
👍️0
Golden Cross Golden Cross 3 hours ago
Nice buy volume so far...$TLSA
👍️0
Golden Cross Golden Cross 4 hours ago
$TLSA Strong Uptrend Underway! Green 5 of the last 6 days. Great news out today! Looking strong here!

👍️0
Mpphotopro Mpphotopro 5 hours ago
Good news and chart is primed for a run 
👍️0
Golden Cross Golden Cross 6 hours ago
$TLSA Wall Street’s Next Obsession? Alzheimer’s Drugs Could Rival Weight Loss Boom
https://www.wallstreetpr.com/wall-streets-next-obsession-alzheimers-drugs-could-rival-weight-loss-boom-64911?fbclid=IwY2xjawIhcLVleHRuA2FlbQIxMAABHS_a-vHAhNhl9IssSY6xmJoDpRqR-jM0svkp2wVIfgxnJUxBSrmXvStVfw_aem_rTrKWH-ulU9iS9QENAY3-A
👍️0
Golden Cross Golden Cross 14 hours ago
Heading that way... Plenty of time...
👍️0
hssbwwmp hssbwwmp 14 hours ago
When will Tomorrow's Blue Chip Alzheimer's Stock get back over $1 to cure the deficiency?
👍️0
Golden Cross Golden Cross 24 hours ago
$TLSA Tiziana Life Sciences not to engage in capital raising activities for the immediate future
https://www.tizianalifesciences.com/tiziana-life-sciences-not-to-engage-in-capital-raising-activities-for-the-immediate-future/#:~:text=(Nasdaq%3A%20TLSA)%20(%E2%80%9C,raising%20activities%20for%20the%20immediate
👍️0
Golden Cross Golden Cross 1 day ago
$TLSA Tomorrow's Blue Chip Alzheimer's Stock
https://allcapresearch.com/f/tiziana-life-sciences-tlsa-advances-alzheimers-treatment?fbclid=IwY2xjawIbXIdleHRuA2FlbQIxMAABHe51nzMbOAONcwXeUUosZEUrMLKVlQlfegQrLNedZ7HJrIu5cfklHoVR8w_aem_us9Sw-zI6RGhWAbM1KKsug
👍️0
Golden Cross Golden Cross 2 days ago
$TLSA Tiziana Life Sciences: Advancing Nasal Delivery Immunotherapies for Enhanced Safety & Efficacy
https://www.youtube.com/watch?v=MDy7pg4EDM8

👍️0
Golden Cross Golden Cross 3 days ago
$TLSA Strong Upswing Underway! Green 5 of the last 6 days! Chart Very Bullish Here! RSI and MACD getting more bullish. Strong accumulation! Looking like we are heading much higher!

👍️0
Golden Cross Golden Cross 4 days ago
$TLSA Massachusetts man first to try new Alzheimers nasal spray treatment
https://www.youtube.com/watch?v=vj6GGzbJfOk

👍️0
Mpphotopro Mpphotopro 4 days ago
$TLSA taking the next step in alzheimer curing!   This could be monstrous 
👍️0
Golden Cross Golden Cross 5 days ago
$TLSA Tiziana Life Sciences Advances Alzheimer's Treatment
https://allcapresearch.com/f/tiziana-life-sciences-tlsa-advances-alzheimers-treatment?fbclid=IwY2xjawIbXIdleHRuA2FlbQIxMAABHe51nzMbOAONcwXeUUosZEUrMLKVlQlfegQrLNedZ7HJrIu5cfklHoVR8w_aem_us9Sw-zI6RGhWAbM1KKsug
👍️0
Bandicoot_Inv Bandicoot_Inv 1 week ago
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab



👍️0
hssbwwmp hssbwwmp 3 weeks ago
What is wrong with TLSA after all the positive news lately? Why is the pps going down instead of up?
👍️0
tw0122 tw0122 4 weeks ago
.80 TLSA ..03:30 PM EST, 01/23/2025 (MT Newswires) -- Tiziana Life Sciences (TLSA) said Thursday that preclinical studies of foralumab, a nasal anti-CD3 monoclonal antibody, in traumatic spinal cord injury showed notable improvements in motor functions.
👍️0
weedtrader420 weedtrader420 4 weeks ago
☝️😁☝️🌎🚀
👍️0
glenn1919 glenn1919 4 weeks ago
tlsa......................https://stockcharts.com/h-sc/ui?s=tlsa
&p=W&b=5&g=0&id=p86431144783
👍️0
PonkenPlonken PonkenPlonken 4 weeks ago
now at my entry
👍️0
subslover subslover 4 weeks ago
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab. We believe these findings contribute substantially to our understanding of the immune mechanisms underlying the effects of nasal foralumab.

The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include modulation of:

FoxP3 T regulatory cells (Tregs)
CD4+ and CD8+ central memory T cells
CD14+ and CD14- monocytes
Naïve B cells
These pathways are known to be associated with antigen presentation, interferon responses, and other regulatory immune mechanisms.

In this study, single-cell RNA sequencing (scRNAseq) of peripheral blood samples taken before and at three and six months after drug administration has revealed relevant gene expression changes associated with nasal foralumab, which has been associated with a reduction in microglial brain inflammation, as measured by advanced microglial PET scans in these same patients.

“We are excited to announce this breakthrough in understanding how nasal foralumab induces immune modulation in Secondary Progressive MS patients,” said Dr. Tanuja Chitnis, M.D., Principal Investigator and Professor of Neurology at Harvard Medical School and senior neurologist at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System. “These findings highlight the potential of nasal foralumab in modulating critical immune pathways and offer new insights into its clinical effects. This discovery represents a pivotal step toward personalized treatment strategies for MS. We look forward to submitting these data to a peer reviewed journal.”

“The observed clinical stabilization and microglial PET findings are supported by these new biomarker discoveries, providing compelling evidence of nasal foralumab's biological effects,” said Dr. Howard Weiner, Chairman of Tiziana’s Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham healthcare system. “The identification of these biomarkers not only strengthens our understanding of the treatment’s mechanism but also establishes a framework for monitoring its efficacy in future trials and may establish a framework for monitoring a patient’s response to foralumab treatment.”

“This data, and its implications, underscores our commitment to advancing innovative therapies for neurodegenerative diseases,” commented Ivor Elrifi, CEO of Tiziana Life Sciences. “Foralumab, the first fully human anti-CD3 monoclonal antibody, is in a Phase 2 trial as a groundbreaking immunomodulatory therapy with applications in autoimmune and neurodegenerative diseases. These findings further confirm its potential and set the stage for broader clinical exploration.”

The FDA defines a biomarker as a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. A biomarker is not an assessment of how an individual feels, functions, or survives.

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program with either an improvement or stability of disease seen within 6 months in all patients. The FDA has recently allowed an additional 20 patients to be enrolled in this EA program. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal
👍️0
PonkenPlonken PonkenPlonken 2 months ago
Someone is on the bid.... Late MS - only one out there
👍️0
PonkenPlonken PonkenPlonken 4 months ago
TLSA for progressive MS
smart and genuine CEO in good "company"
https://en.wikipedia.org/wiki/Howard_L._Weiner
https://finance.yahoo.com/news/tiziana-life-sciences-announces-live-110000183.html
👍️0
Monksdream Monksdream 4 months ago
TLSA under $2
👍️0
Monksdream Monksdream 6 months ago
TLSA under $2
👍️0
glenn1919 glenn1919 6 months ago
TLSA.........................https://stockcharts.com/h-sc/ui?s=TLSA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
TLSA...FULL OUT WEEKLY BREAK OUT!!!!
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
TLSA...NEXT BIO BEAST READY TO FLY, NOT A BETTER CHART OUT THERE
👍️0
Monksdream Monksdream 7 months ago
TLSA 10Q expected JULY8
👍️0
Monksdream Monksdream 8 months ago
TLSA 10Q expected July 1
👍️0
Monksdream Monksdream 8 months ago
TLSA 10Q expected Monday 6/24
👍️0
Monksdream Monksdream 12 months ago
TLSA new 52 week low

👍️0
mfayman mfayman 1 year ago
Alot of room here
👍️0
mfayman mfayman 1 year ago
The 9s + breakout coming
👍️0
mfayman mfayman 1 year ago
Green day!! Volumes been consistent getting into a groove here
👍️0
Cameo Brien Cameo Brien 1 year ago
https://newsdirect.com/news/tiziana-life-sciences-reports-six-month-pet-scan-results-for-ms-patients-545441035
👍️ 1
Ryguy008 Ryguy008 1 year ago
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment https://www.globenewswire.com/news-release/2023/10/18/2762186/0/en/Tiziana-Life-Sciences-Announces-Allowance-By-FDA-For-At-Home-Dosing-Of-Intranasal-Foralumab-For-Multiple-Sclerosis-Treatment.html

$TLSA
👍️0
Cameo Brien Cameo Brien 1 year ago
News

https://marketwirenews.com/news-releases/tiziana-life-sciences-announces-allowance-by-fda-for-8463755861297756.html
👍️0
Cameo Brien Cameo Brien 1 year ago
https://marketwirenews.com/articles/tiziana-life-sciences-plc-nasdaq-tlsa-short-squeeze--mwn-news-4013.html
👍️0
Cameo Brien Cameo Brien 1 year ago
Easy imo
👍️0
Cameo Brien Cameo Brien 1 year ago
Gm all
👍️0
Anita Dump Anita Dump 1 year ago
coffee and DD
👍️0
Anita Dump Anita Dump 1 year ago
good setup to pop from here
👍️0
Anita Dump Anita Dump 1 year ago
under the radar $TLSA
👍️0
Anita Dump Anita Dump 1 year ago
$1 yup
👍️0
mfayman mfayman 1 year ago
Next stop 1$ +
👍️0
Anita Dump Anita Dump 1 year ago
im in
👍️0
Cameo Brien Cameo Brien 1 year ago
Same here
👍️0
Ryguy008 Ryguy008 1 year ago
$TLSA keeping an eye here
👍️0

Your Recent History

Delayed Upgrade Clock